A dual 6‐month (stage 1) & 18‐month (stage 2) prospective, randomized, placebo‐controlled, double‐blind, pivotal clinical trial investigating efficacy and safety of buntanetap in early Alzheimer's patients

Tables will be featured on the poster showing the status of the following per July 2025: • An update of the recruiting sites and locations • A US map with all site locations shown as pins, to highlight regional study access • pTau217 selection inclusion/exclusion figures • Current enrollment versus Target enrollment of 760 participants • Actual monthly participant accrual versus projected monthly accrual • Estimated timelines for the 6-month and 18-month end of study data readouts • Screen failure rate with breakdown of screen failure reasons CONCLUSION: In summary, we will show the ease of using plasma biomarkers to determine the presence of AD. We will provide updates on total enrollment and the 6- and 18-month data readout timepoints.